Compare NOMD & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NOMD | VRDN |
|---|---|---|
| Founded | 2014 | 2006 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Medical Specialities |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | 2015 | 2014 |
| Metric | NOMD | VRDN |
|---|---|---|
| Price | $10.34 | $15.91 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 14 |
| Target Price | $12.50 | ★ $35.46 |
| AVG Volume (30 Days) | 1.5M | ★ 3.0M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 7.11% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,706,000.00 |
| Revenue This Year | N/A | $13.73 |
| Revenue Next Year | $1.45 | $279.00 |
| P/E Ratio | $8.38 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.99 | $13.18 |
| 52 Week High | $18.33 | $34.29 |
| Indicator | NOMD | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 60.33 | 44.79 |
| Support Level | $9.47 | $15.68 |
| Resistance Level | $10.46 | $19.72 |
| Average True Range (ATR) | 0.40 | 0.91 |
| MACD | 0.10 | 0.38 |
| Stochastic Oscillator | 86.89 | 39.68 |
Nomad Foods Ltd is a packaged foods company that is involved in the business of manufacturing and distributing branded frozen foods in Western Europe. The company manufactures and markets frozen food products such as fish, vegetables, poultry, Ice Cream, and ready meals like pizza. It sells its products through large grocery retailers under the brand Birds Eye in the United Kingdom and Ireland, Findus in Italy, France, Spain, and Iglo in Germany and other continental markets. The company operates through a single segment being Frozen. The majority of the revenue is generated from the United Kingdom.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.